Teduglutide

Overview

Teduglutide, marketed as Gattex in the United States and Revestive in other regions, is an analog of glucagon-like peptide-2 (GLP-2), a hormone produced naturally in the intestine. It is FDA-approved for the treatment of short bowel syndrome (SBS), a serious condition in which a substantial portion of the small intestine has been surgically removed or is non-functional, leaving patients unable to absorb enough nutrients and fluids from food.

Many people with short bowel syndrome depend on parenteral support, intravenous nutrition and fluids delivered through a catheter, often for many hours each day. This dependence carries significant burdens and risks, including bloodstream infections and liver complications. Teduglutide was developed to improve the intestine's absorptive capacity and thereby reduce reliance on parenteral support.

The peptide is given by subcutaneous injection. Unlike the more familiar GLP-1 drugs used in diabetes and weight management, teduglutide acts specifically on GLP-2 receptors concentrated in the gut. It represents a targeted, mechanism-based therapy for a rare condition, addressing the underlying problem of insufficient intestinal absorption rather than merely supplementing nutrition externally.

How it works

GLP-2 is released by specialized cells in the intestinal lining after eating and acts as a growth and adaptation signal for the gut. Native GLP-2 is rapidly broken down by an enzyme called dipeptidyl peptidase-4 (DPP-4), giving it a very short duration of action. Teduglutide is engineered with a small structural modification that resists this degradation, allowing it to remain active far longer and produce sustained effects.

By stimulating GLP-2 receptors in the intestine, teduglutide promotes growth of the intestinal mucosa, the absorptive inner surface. It increases the height of the villi and the depth of the crypts, expanding the surface area available to absorb nutrients and fluids. It also slows gastric emptying and intestinal transit and may increase blood flow to the gut, giving remaining intestine more time and capacity to absorb.

The net result is improved fluid and nutrient absorption, which allows many patients to reduce the volume and frequency of parenteral support. Because the drug actively promotes tissue growth, this same trophic effect underlies certain monitoring requirements, since stimulated proliferation must be watched for unintended consequences in the gut and elsewhere.

Clinical evidence

Teduglutide's approval rested on randomized, placebo-controlled trials in adults with short bowel syndrome dependent on parenteral support, with subsequent studies extending evidence to children. The primary measure of benefit was the reduction in parenteral support volume. A meaningful proportion of treated patients achieved clinically significant reductions, and some were able to reduce the number of days per week they required infusions. A subset of patients achieved independence from parenteral support entirely, though this outcome is not universal.

The response develops gradually over months as the intestine adapts, and benefit can vary considerably between individuals depending on their remaining bowel anatomy. Long-term extension studies suggested that reductions in parenteral support could be maintained with continued treatment, though sustained therapy is generally required to preserve the effect.

The evidence supports teduglutide as a genuinely disease-modifying option for a difficult, life-altering condition, while acknowledging that it does not cure short bowel syndrome and does not help every patient. Because SBS is rare, trial populations were relatively small, and ongoing real-world and registry data continue to refine understanding of who benefits most and how durable the response is over many years.

Dosing & side effects

This guide does not provide dosing figures. Teduglutide is prescribed and titrated by specialists, typically gastroenterologists experienced in intestinal failure, and administered by subcutaneous injection with dose adjustments based on kidney function and clinical response. Treatment requires careful coordination with adjustments to parenteral support as absorption improves.

The drug's growth-promoting mechanism drives its most important safety considerations. Because it stimulates intestinal tissue proliferation, guidelines call for colonoscopy to assess for polyps before starting and periodically thereafter, with removal of any polyps found. There is also concern about the potential to accelerate growth of pre-existing malignancies, so teduglutide is generally avoided in patients with active gastrointestinal cancer.

Common side effects include abdominal pain and distension, nausea, injection-site reactions, headache, and fluid overload. Patients with a stoma may experience swelling of the stoma. Teduglutide can also affect absorption of oral medications, which may require monitoring. Gallbladder, biliary, and pancreatic conditions warrant periodic evaluation as well. Overall, the trophic action that makes the drug effective is inseparable from a monitoring framework designed to catch unwanted tissue growth early, underscoring why specialist oversight is essential.

Legal status

Teduglutide is an FDA-approved prescription medication in the United States, sold as Gattex, and is approved in many other countries under the name Revestive. It is indicated for the treatment of short bowel syndrome in patients who are dependent on parenteral support. As an orphan drug for a rare disease, it occupies a specialized place in clinical care and is typically managed through specialist centers.

As a prescription pharmaceutical, teduglutide can only be obtained through a licensed clinician and dispensed by a pharmacy, often via specialty pharmacy channels given its cost and handling requirements. It is not a controlled substance, but its use is appropriately confined to medical supervision because of the monitoring obligations tied to its mechanism.

Regulatory approval and availability differ by country, and access may be shaped by reimbursement and rare-disease programs. Patients should rely solely on properly prescribed, pharmacy-sourced product. Any teduglutide offered through unregulated or research-chemical outlets would fall outside lawful medical use and raise serious concerns about authenticity, sterility, and safety. Decisions about this therapy belong with a qualified specialist who can weigh its benefits against its risks for the individual patient.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition requirements in short bowel syndrome. Gut. 2011. Peer-reviewed study
2. Tappenden KA, Edelman J, Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol. 2013. Peer-reviewed study
3. Burness CB, McCormack PL. Teduglutide: a review of its use in the treatment of short bowel syndrome. Drugs. 2013. Peer-reviewed study
4. Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012. Peer-reviewed study
5. Rosete BE, Wendel D, Horslen SP. Teduglutide for pediatric short bowel syndrome patients. Expert Rev Gastroenterol Hepatol. 2021. Peer-reviewed study
6. Teduglutide for short bowel syndrome. Aust Prescr. 2020. Peer-reviewed study